Eli Lilly-Backed Terns Reports Positive Phase 1 Results for TERN-101 in NASH
20 February 2020 - 2:38AM
Dow Jones News
By Colin Kellaher
Terns Pharmaceuticals Inc. on Wednesday reported positive
results of a phase 1 study of TERN-101 in non-alcoholic
steatohepatitis, a chronic liver condition commonly known as
NASH.
Terns, a privately held biopharmaceutical company backed by Eli
Lilly & Co., said the study showed all dose levels of TERN-101
were well tolerated and achieved potentially therapeutic-level
target engagement.
Terns in 2018 signed an exclusive licensing agreement with Eli
Lilly to develop, manufacture and commercialize three small
molecule therapeutic candidates, including TERN-101, for the
potential treatment of NASH.
The company said its plans to launch phase 2 studies of TERN-101
in NASH patients in mid-2020.
Terns was launched in April 2017 with $30 million in Series A
funding led by Lilly Asia Ventures, whose investors include Eli
Lilly. Lilly Asia Ventures also participated in an $80 million
Series B financing round in October 2018.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 19, 2020 10:23 ET (15:23 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2024 to May 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From May 2023 to May 2024